Risk factor
Low default risk
Profitability factor
Very strong margins and returns
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | +0.00% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | -0.00% |
About
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBIT
Target Price
The average target price of NOVO-B.CO is 319 and suggests 3.93% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommend